Education
About Us
Working with TipRanks
Follow Us
MedinCell SA (FR:MEDCL)
:MEDCL
Earnings Data
Report Date
Jun 16, 2026During Market Hours (Confirmed)
Period Ending
2026 (Q4)Consensus EPS Forecast
0.01Last Year’s EPS
-0.12Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for MedinCell, emphasizing significant milestones such as the FDA filing of Olanzapine LAI and robust growth in UZEDY sales. Despite some financial challenges due to currency fluctuations and non-cash impacts, the company's strategic initiatives and pipeline expansions suggest a promising future.Company Guidance
Olanzapine LAI FDA Filing
Teva filed the Olanzapine LAI at the FDA, with a potential approval expected in Q4 2026. This filing is seen as a major milestone for MedinCell and is expected to significantly accelerate growth.
UZEDY Sales Growth
UZEDY's prescription growth continues, with Teva confirming sales guidance of $190 million to $200 million for 2025. UZEDY is also approved for the treatment of bipolar I disorder in the U.S. and has been launched in South Korea and Canada.
R&D Revenue Increase
MedinCell reported a 50% increase in revenue for the period, largely due to R&D partnerships and increased royalties from UZEDY, which accounted for a third of the revenue.
Pipeline Expansion
MedinCell announced it will launch its first program with AbbVie into Phase I in 2026, with potential milestones of $315 million and royalties in the low double digits.
Financial Position
The company ended September with EUR 53 million in cash, providing visibility for at least two years. The cash position supports ongoing R&D investments and future growth.
FR:MEDCL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
FR:MEDCL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Dec 09, 2025 | €26.68 | €26.48 | -0.75% |
Jun 17, 2025 | €15.49 | €15.05 | -2.84% |
Dec 10, 2024 | €16.78 | €17.10 | +1.91% |
Jun 10, 2024 | €15.12 | €14.88 | -1.59% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does MedinCell SA (FR:MEDCL) report earnings?
MedinCell SA (FR:MEDCL) is schdueled to report earning on Jun 16, 2026, During Market Hours (Confirmed).
What is MedinCell SA (FR:MEDCL) earnings time?
MedinCell SA (FR:MEDCL) earnings time is at Jun 16, 2026, During Market Hours (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of MedinCell SA stock?
The P/E ratio of MedinCell SA is N/A.
What is FR:MEDCL EPS forecast?
FR:MEDCL EPS forecast for the fiscal quarter 2026 (Q4) is 0.01.